“At AstraZeneca, we firmly believe that the combination of science, technology, and clinical expertise is essential to transforming healthcare and building more equitable and sustainable health systems. Breast cancer presents complex challenges that require innovation, collaboration, and a connected healthcare ecosystem. For this reason, in partnership with EIT Health and SERMAS, we are driving initiatives that integrate AI and personalised medicine. Our mission is to enhance diagnostics, optimise treatments, reduce inequalities in healthcare access, and maximise the efficiency of healthcare resources, reaffirming our commitment to patient-centered innovation.”

“At AstraZeneca, we are committed to identifying and providing specialists with solutions that address unmet needs in oncology. Our project to prioritise the implementation of biomarker testing in breast cancer tackles one of today’s key gaps: the lack of equitable access to advanced diagnostic tools and personalised treatments. By incorporating technologies such as AI, we not only enhance diagnostic precision but also equip healthcare professionals with innovative alternatives to optimise diagnosis and treatment. This approach strengthens our purpose of advancing precision medicine, which, in addition to improving quality of life and cancer survival, ensures more equitable and effective care”.

“Our collaboration with EIT Health and industry partners such as AstraZeneca is vital to developing solutions that not only respond to complex challenges such as breast cancer but also promote more personalised and accessible care. This integrated approach ensures that innovations in healthcare are not only possible but are effectively implemented to improve the quality of life of patients, demonstrating our commitment to a healthcare system that prioritises equity and service excellence.”

“At SERMAS, we care for persons with cancer from early signs and screening to diagnosis, treatment and follow-up. Hospital breast cancer units are a major asset in the clinical management of patients and provide an integrative and multidisciplinary approach. We expect the EIT Health Open Innovation Challenge to address critical patient needs and bring new tools for healthcare professionals to overcome the barriers that slow down the implementation of guideline recommendations and the uptake of new therapies. If the recent progress in molecular diagnosis and personalised treatment is put into practice along the patient journey, we will be able to further improve the quality of life and outcome of women with breast cancer.”